Gastroenterology and Hepatology
Gastroenterology is a branch of medicine that deals with normal function and diseases that affect the digestive tract, from mouth to anus and includes hepatology involving the study of the liver, pancreas, gallbladder and biliary tree.
Acute Hepatic Porphyria Learning Zone
Acute Hepatic Porphyria (AHP), a subset of porphyria, refers to a family of rare, genetic diseases characterised by potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of life (QOL).1 The most common manifestation of attacks is severe, diffuse abdominal pain, although patients can also experience other pain, mood, and gastrointestinal (GI) symptoms.
Featured Learning Zones
Welcome to the Fluid Management Learning Zone. In this Learning Zone we provide an overview of fluid management, including albumin for sepsis and septic shock, guidelines for fluid management in liver cirrhosis and fluid management in cardiac surgery.
Optimising anti-TNF treatment using biosimilars
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Inflammatory Bowel Disease
Treatment options for inflammatory bowel disease (IBD) are evolving as knowledge of the condition is increasing. In the future, physicians may be able to offer therapy tailored to individual patients. This Learning Zone describes the background behind such advances.
Gastroenterology focuses on the diagnosis and treatment of conditions such gastrointestinal disorders including acute hepatic porphyria, bowel disorders including inflammatory bowel disease, Crohn’s disease, as well as Coeliac disease, hepatitis and pancreatic disorders or transplantation.
Related news and insights
AbbVie announced positive results from two Phase III induction studies, ADVANCE and MOTIVATE, showing both doses of Skyrizi (risankizumab) (600 mg and 1200 mg) met both primary endpoints of clinical remission and endoscopic response at week 12 in adult patients with moderate to severe Crohn's disease.
Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC).
Hepatitis B is a common infectious disease that can result in progressive liver damage requiring liver transplantation. Due to the high prevalence of hepatitis B infection worldwide many patients who are transplanted with other solid organs will...
Early recognition and intervention is essential for survival. The immediate priorities are to control bleeding (surgery and interventional radiology) and maintain vital organ perfusion by transfusing blood and other fluids through...